glp-1 agonist eli lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating GLP-1 use tripled among non-diabetics,

There are no published clinical trials specifically studying GLP-1 microdosing

Andersen A, Lund A, Knop FK, Vilsboll T (2018) Glucagon-like peptide 1 in health and disease

Construction of Ob/Ob-GAN NASH Mice and Drug Intervention C57BL/6 mice and ob/ob mice were provided free access to tap water and normal chow until they were 25-week-old

Geldmacher DS, Fritsch T, McClendon MJ, Landreth G

Where Shotsy is still better Shotsy is not a weak product

Additionally, they suppress glucagon secretion , slow gastric emptying, and promote satiety through central nervous system pathways, which collectively improve glycaemic control and facilitate weight loss